Targeting a specific protein to prevent pancreatic cancer progression
Official title: Targeting CDK4/6 as an interception strategy for intraductal papillary mucinous neoplasia
Funded at University of California, San Diego · NIH-11033805 · Data updated 2026-11-12
This study is looking at how blocking a specific protein might help people with intraductal papillary mucinous neoplasms (IPMN), which can lead to pancreatic cancer, by using animal models to see if it can slow down tumor growth and help find safer treatment options for those at high risk.
Quick facts
| Grant type | Career grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California, San Diego NIH-funded |
| Lab location | 1 site (La Jolla, United States) |
| Project start | April 1, 2025 |
| Project end | March 31, 2030 |
| Funding year | 2025 |
| Award (this year) | $166,037 |
| NIH project number | 1K01CA297135-01 |
| Project ID | NIH-11033805 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with intraductal papillary mucinous neoplasms, particularly those exhibiting high-risk features.
✕Less likely to help
Patients with low-risk IPMN or those who have already undergone surgical resection may not benefit from this research.
What this research studies
This research investigates how inhibiting the CDK4/6 protein can help manage intraductal papillary mucinous neoplasms (IPMN), which are precursors to pancreatic cancer. The study uses advanced animal models to explore the effects of this inhibition on tumor growth and progression. By focusing on genetic mutations commonly found in IPMN, the research aims to identify effective treatment strategies that could reduce the risk of developing invasive pancreatic cancer. Patients with high-risk IPMN features may benefit from these findings, potentially avoiding the need for risky surgeries.
Why it matters
Potential benefit: If successful, this research could lead to new treatment options that prevent the progression of IPMN to pancreatic cancer, improving patient outcomes.
How similar studies have gone: Previous research has shown promising results with CDK4/6 inhibition in other cancer types, suggesting potential for success in this novel application.
Where this research is happening
-
University of California, San Diego
La Jolla, United States Active
Researchers
- Principal investigator: Weitz, Jonathan Robert — University of California, San Diego
- Study coordinator: Weitz, Jonathan Robert
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.